<DOC>
	<DOCNO>NCT02766348</DOCNO>
	<brief_summary>Patients group A receive DC-CTL treatment chemotherapy . Patients group B receive chemotherapy .</brief_summary>
	<brief_title>Clinical Efficacy Safety Dendritic Cytotoxic Lymphocyte ( DC-CTL ) Cell Infusion NSCLC Patients</brief_title>
	<detailed_description>60 patient stage III-IV NSCLC randomly divide group A ( receive DC-CTL treatment chemotherapy ) group B ( Just receive chemotherapy ) , randomize ratio 1:1 , patient group A receive 3 cycle DC-CTL treatment ( every 1 month ) 4 cycle chemotherapy ( every 2 week ) . Patients group B receive 4 cycle chemotherapy ( every 2 week ) .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>The patient sign informed consent ; Histologically confirm NSCLC stage IIIIV Expected survival time 2 month ; Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Hemoglobin &lt; 8.0 g/dL , White blood cell &lt; 3 x 10^9/L ; Platelet count &lt; 75 x 10^9/L ; alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , blood urea nitrogen ( BUN ) Creatinine ( CR ) normal limit 3.0 time ; Known suspect allergy investigational agent agent give association trial ; Pregnant lactating patient ; Known history Human Immunodeficiency Virus ( HIV ) , Hepatitis C Virus ( HCV ) TreponemaPallidun ( TP ) infection ; Patients suffer serious autoimmune disease ; Patients use long time use immunosuppressant ; Patients active infection ; Patients suffer serious organ dysfunction ; Patients suffer cancer ; Other situation researcher consider unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>DC-CTL , NSCLC</keyword>
</DOC>